



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/524,019
Filing Date	August 23, 2003
First Named Inventor	Masahiko TANIKAWA et al
Group Art Unit	1645
Confirmation No.	7565
Attorney Docket Number	TANIKAWA =1

Sheet 1

of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
TU	BI	US-2003/0092622 A1	05-15-2003	SATO et al	
TU	BQ	US-5,584,994 A	12-17-1996	HATTORI et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ Number ⁵ Kind Code ⁶ (if known)				
TU	BJ	EP 1 329 224 A1	07-23-2003	CHUGAI SEIYAKU KABUSHIKI KAISHA		
TU	BK	EP 1 232 753 A1	08-21-2002	CHUGAI SEIYAKU KABUSHIKI KAISHA		
TU	BL	EP 1 197 221 A1	04-17-2002	CHUGAI SEIYAKU KABUSHIKI KAISHA		
TU	BM	EP 0 178 665 A2	04-23-1986	CHUGAI SEIYAKU KABUSHIKI KAISHA		
TU	BN	JP 2001-340062 A	12-11-2001	KABUSHIKI KAISHA TOYO SHIN'YAKU		
TU	BO	JP 2000-229815 A	08-22-2000	HATTORI, Toshimitsu		
TU	BP	JP 1-262988 a	10-19-1989	KABUSHIKI KAISHA SHOKO KAGAKU KENKYUSHO		

Examiner
Signature

/Thane Underdahl/

Date
Considered

12/13/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/524,019
Filing Date	August 26, 2003
First Named Inventor	Masahiko TANIKAWA et al
Group Art Unit	1645
Confirmation No.	7565
Attorney Docket Number	TANIKAWA =1

Sheet 1

of 3

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
TU	AA	EP 0 239 400 B1	09-30-1987	MEDICAL RESEARCH COUNCIL		
TU	AB	JP 58-201994 A	11-25-1983	HAGIWARA HIDEAKI		Abs
TU	AC	JP 61-12288 A	01-20-1986			Trans
TU	AD	JP 1-59878 B2	12-20-1989	HAGIWARA HIDEAKI		Abs
TU	AE	JP 08-151398 A	08-11-1996	AMGEN		Abs
TU	AF	JP 11-092399 A	04-06-1999	CHUGAI PHARMACEUT CO LTD		Abs
TU	AG	JP 2001-503781 A	03-21-2001			Trans
TU	AH	JP 08-506023 A	07-02-1996			Trans
TU	AI	WO 95/05465 A1	02-23-1995	AMGEN		
TU	AJ	WO 90/12874 A2	11-01-1990	GENETICS INSTITUTE, INC.		
TU	AK	WO 92/01047 A1	01-23-1992	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED; MEDICAL RESEARCH COUNCIL		
TU	AL	WO 92/03918 A1	03-19-1992	GENPHARM INTERNATIONAL INC.		
TU	AM	WO 92/19759 A1	11-12-1992	CHUGAI PHARMACEUTICAL CO., LTD.		Abs
TU	AN	WO 92/20791 A1	11-28-1992	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED; MEDICAL RESEARCH COUNCIL		
TU	AO	WO 93/06213 A1	04-01-1993	MEDICAL RESEARCH COUNCIL; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED		
TU	AP	WO 93/11236 A1	06-10-1993	MEDICAL RESEARCH COUNCIL; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED		
TU	AQ	WO 93/12227 A1	06-24-1993	GENPHARM INTERNATIONAL, INC.		
TU	AR	WO 93/19172 A1	09-30-1993	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED; MEDICAL RESEARCH COUNCIL		

Examiner
Signature

/Thane Underdahl/

Date
Considered

12/13/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2
-------	---

2

Q

3

Attorney Docket Number

TANIKAWA = 1

Complete if Known

Application Number	10/524,019
--------------------	------------

Filing Date	August 23, 2003
-------------	-----------------

First Named Inventor	Masahiko TANIKAWA et al
----------------------	-------------------------

Group Art Unit	1645
----------------	------

Confirmation No.	7565
------------------	------

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Thane Underdahl/

Date Considered

12/13/2006.

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of 3

Complete if Known

Application Number	10/524,019
Filing Date	August 23, 2003
First Named Inventor	Masahiko TANIKAWA et al
Group Art Unit	1645
Confirmation No.	7565
Attorney Docket Number	TANIKAWA =1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
TU	BD	BORREBAECK, Carl and James Larrick. Eds. Therapeutic Monoclonal Antibodies. 1990. London, UK, Macmillan Publishers Ltd.	
TU	BE	GALFRE, G. and C. Milstein. "Preparation of Monoclonal Antibodies: Strategies and Procedures". Methods in Enzymology, 1981. 73:3-46.	
TU	BF	SATO, Koh, et al. "Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell". Cancer Research. February 15, 1993. 53:851-856.	
TU	BG	THE EUROPEAN PHARMACOPOEIA. "Particulate Contamination: Visible Particles".. 1997. Third edition, Section 2.9.20. pp. 150-153.	
TU	BH	THE JAPANESE PHARMACOPOEIA. "Test for Insoluble Particles in Injections, Standard Test Procedures". JP XIV. Sections 23 and 24. pp. 44-47.	

Examiner
Signature

/Thane Underdahl/

Date
Considered

12/13/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.